LivaNova (NASDAQ:LIVN) issued an update on its FY19 earnings guidance on Wednesday morning. The company provided EPS guidance of $3.00-3.10 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.03. The company issued revenue guidance of +1-3% yr/yr to $1.2-1.4 billion, compared to the consensus revenue estimate of $1.11 billion.LivaNova also updated its FY 2019 guidance to $3.00-3.10 EPS.
LivaNova stock traded up $0.69 during trading hours on Wednesday, hitting $76.42. The stock had a trading volume of 15,984 shares, compared to its average volume of 314,251. The company’s 50-day simple moving average is $72.81. The company has a debt-to-equity ratio of 0.13, a quick ratio of 0.61 and a current ratio of 0.87. The stock has a market cap of $3.60 billion, a P/E ratio of 24.24, a PEG ratio of 3.14 and a beta of 0.57. LivaNova has a fifty-two week low of $64.80 and a fifty-two week high of $131.54.
LivaNova (NASDAQ:LIVN) last announced its quarterly earnings data on Wednesday, May 1st. The company reported $0.54 EPS for the quarter, beating the Zacks’ consensus estimate of $0.43 by $0.11. The firm had revenue of $250.80 million for the quarter, compared to analyst estimates of $254.89 million. LivaNova had a positive return on equity of 9.38% and a negative net margin of 19.64%. The business’s quarterly revenue was up .2% compared to the same quarter last year. During the same period last year, the company earned $0.68 EPS. On average, equities analysts anticipate that LivaNova will post 2.6 earnings per share for the current fiscal year.
In related news, Director Alfred J. Novak sold 1,300 shares of the company’s stock in a transaction dated Thursday, May 9th. The shares were sold at an average price of $70.63, for a total value of $91,819.00. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director William A. Kozy acquired 1,000 shares of the firm’s stock in a transaction on Thursday, May 2nd. The stock was purchased at an average price of $72.81 per share, with a total value of $72,810.00. The disclosure for this purchase can be found here. Insiders have sold a total of 5,300 shares of company stock worth $387,999 in the last three months. Insiders own 0.41% of the company’s stock.
LivaNova Company Profile
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients.
See Also: Why is the price-sales ratio important?
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.